Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02376972 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis
A Phase 2 study, sponsored by Alfasigma S.p.A..
- Terminated
- Registry status
- Phase 2
- Development phase
- 392
- Enrollment target
NCT02376972 is a Phase 2 study that was terminated before completion, run by Alfasigma S.p.A.. The registered enrollment target is 392 participants.
The verdict
NCT02376972, a Phase 2 study, was terminated before completion, sponsored by Alfasigma S.p.A..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 392 participants
- Enrollment target
Study Summary
THE STUDY HAS BEEN DESIGNED TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS
Interventions
- DRUG RIFAXIMIN VAGINAL TABLET 25 MG
- DRUG RIFAXIMIN VAGINAL TABLET 100 MG
- DRUG PLACEBO VAGINAL TABLET
- DRUG METROGEL VAGINAL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 392 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02376972
The ClinicalTrials.gov registry entry for NCT02376972 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 392 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alfasigma S.p.A., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which RIFAXIMIN VAGINAL TABLET 25 MG is the first listed.
NCT02376972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02376972 about?
NCT02376972 is a clinical study titled "Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis". THE STUDY HAS BEEN DESIGNED TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS
What is the current status of trial NCT02376972?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 392 participants. The study started on 2015-04. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02376972?
The interventions under investigation include: RIFAXIMIN VAGINAL TABLET 25 MG (DRUG), RIFAXIMIN VAGINAL TABLET 100 MG (DRUG), PLACEBO VAGINAL TABLET (DRUG), METROGEL VAGINAL (DRUG).
Who is sponsoring clinical trial NCT02376972?
This trial is sponsored by Alfasigma S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.